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ABSTRACT
This study characterised non-multiresistant methicillin-resistant Staphylococcus aureus (nmMRSA)
isolates from Kuwait hospitals to ascertain whether they were community-acquired MRSA (CA-
MRSA). Forty-two nmMRSA isolates obtained between July 2001 and October 2003 were analysed by
staphylococcal cassette chromosome mec (SCCmec) typing, bacteriophage typing, production of
Panton-Valentine leukocidin (PVL), urease and staphylococcal enterotoxins A, B, C and D, TSST-1,
and by pulsed-field gel electrophoresis (PFGE). Forty-one isolates were SCCmec type IV, and one isolate
was SCCmec type III. The isolates belonged to six PFGE patterns, with two types, A and D, distributed in
six and four hospitals, respectively. Most (n = 26; 61.9%) isolates produced urease. These isolates were
mainly from wound and skin infections, showed low-level methicillin resistance (MIC 8–48 mg ⁄L), and
nine carried genes for PVL. These characteristics, together with their carriage of the type-IV SCCmec,
identified the isolates as CA-MRSA. Ten of the 16 urease-negative isolates produced staphylococal
enterotoxin C; 12 reacted weakly with phage 75, and were resistant to clindamycin and ⁄ or
erythromycin, which are characteristics of EMRSA-15. Thus, this study identified the co-existence of
two types of nmMRSA, i.e., CA-MRSA and EMRSA-15, in Kuwait hospitals.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
is an established pathogen causing hospital-
acquired infections worldwide. MRSA was asso-
ciated initially with hospitals and other healthcare
facilities, such as nursing homes and long-term
care facilities [1,2]. However, a new type of MRSA
causing infections in the community has now
been described in many countries [3–10]. These
new MRSA strains, described variously as
community-acquired or community-originated
MRSA (CA-MRSA) or non-multiresistant MRSA
(nmMRSA) were isolated initially from individu-
als residing in remote communities with no access
to healthcare centres [3–5] and with none of the
risk-factors associated traditionally with hospital-
acquired MRSA (e.g., recent hospitalisation, trans-
fer from another hospital, preceding use of anti-
microbial agents, invasive procedures and
underlying disease) [1,2]. CA-MRSA have also
been isolated from hospitalised patients and, in a
few instances, have been involved in outbreaks of
hospital infection [10–13].
Recent studies have described characteristics
that differentiate CA-MRSA from healthcare-
associated MRSA (HA-MRSA) strains [14–17].
CA-MRSA tend to be susceptible to a variety of
non-b-lactam antibiotics, whereas HA-MRSA are
typically resistant to multiple antibiotics. In
addition, CA-MRSA strains harbour a novel
methicillin resistance gene cassette element
(staphylococcal cassette chromosome mec
(SCCmec) type IV) [14], whereas HA-MRSA carry
SCCmec types I, II and III, and also carry a set of
site-specific recombinase genes, cassette chromo-
some recombinase genes ccrA and ccrB, which are
responsible for the integration and excision of
SCCmec and the mecA gene complex [17].
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CA-MRSA are also more likely than HA-MRSA
isolates to encode a putative virulence factor,
Panton-Valentine leukocidin (PVL) [6–
9,11,12,18,19], which is a cytotoxin that has been
associated with severe pneumonia [7], necrotising
fasciitis [20] and skin and soft-tissue infections
[7,12], Furthermore, CA-MRSA often express
lower levels of resistance to oxacillin (MIC 8–
32 mg ⁄L) and multiply faster, with significantly
shorter doubling times than HA-MRSA strains,
which may contribute to successful colonisation
with CA-MRSA by enabling them to out-compete
commensal bacterial flora [21].
Although infections caused by CA-MRSA are
increasing worldwide [2–10,21,22], the preval-
ence of CA-MRSA in Kuwait and other Gulf
countries has been uncertain because of an
absence of any population-based surveillance
for these strains. Consequently, a retrospective
review of the susceptibility patterns of MRSA
submitted to the MRSA reference laboratory for
typing was performed to detect the presence of
nmMRSA. A review of susceptibility records
showed that MRSA isolated in Kuwait hospitals
prior to July 2001 were multiresistant. However,
nmMRSA began to appear among isolates
obtained from different hospitalised patients in
July 2001. The aim of the present study was to
investigate isolates of nmMRSA by SCCmec
typing, bacteriophage typing, production of
urease, staphylococcal enterotoxins and TSST-1,
and for the presence of genes for PVL, to
ascertain whether they were CA-MRSA. The
isolates were also typed by phenotypic and
genotypic methods to determine their genetic
relatedness.
MATERIALS AND METHODS
MRSA isolates
The MRSA isolates studied were selected from isolates
submitted for typing between July 2001 and October 2003 to
the national MRSA Reference Laboratory (Department of
Microbiology, Faculty of Medicine, Kuwait University,
Kuwait). The isolates were submitted from seven hospitals,
the Al Sabah (ASH), Adan (ADH), Al Razi (ARH), Amiri
(AMH), Mubarak (MAK), Jahra (JH) and Ibn Sina (ISH)
hospitals, where they were identified on the basis of cultural
characteristics, Gram’s stain, and positive tube coagulase and
DNase tests. The isolates were preserved in glycerol 15% v ⁄v
in brain heart infusion broth (BHIB; Oxoid, Basingstoke, UK) at
) 80C. The isolates were recovered by subculturing in BHIB at
37C for 24 h, followed by two further subcultures on brain
heart infusion agar.
Susceptibility to antimicrobial agents
Susceptibilities were determined by the disk-diffusion method
[23] on Mueller-Hinton Agar (Oxoid), with antibiotic disks
(Oxoid) containing methicillin 5 lg, benzyl penicillin 2 U,
cefoxitin 30 lg, kanamycin 30 lg, fosfomycin 30 lg, mupirocin
200 lg, gentamicin 10 lg, erythromycin 15 lg, clindamycin
2 lg, chloramphenicol 30 lg, tetracycline 10 lg, trimethoprim
2.5 lg, fusidic acid 10 lg, rifampicin 5 lg, ciprofloxacin
5 lg, teicoplanin 30 lg, vancomycin 30 lg or linezolid
30 lg. Additional non-antibiotic-containing disks were
prepared in the laboratory and contained cadmium
acetate 50 lg, propamidine isethionate 100 lg or mercuric
chloride 109 lg. MICs of methicillin, vancomycin and teicopl-
anin were determined by Etest (AB Biodisk, Solna, Sweden)
according to the manufacturer’s instructions. S. aureus
strain ATCC25923 was used as a quality control strain for
susceptibility testing. Methicillin resistance was confirmed
by detecting PBP2a with a rapid latex agglutination kit
(Denka-Seiken, Tokyo, Japan), used according to the manu-
facturer’s instructions.
Bacteriophage typing
Bacteriophage typing was performed on all isolates by the
method of Blair and Williams [24] with the basic international
set of 23 phages for S. aureus (group I, phages 29, 52, 52A, 79
and 80; group II, phages 3A, 3C, 55 and 71; group III, phages 6,
42E, 47, 53, 54, 75, 77, 83A, 84 and 85; group V, phages 94 and
96; and miscellaneous, phages 81 and 95). All phages were
used at 100· the routine test dilution.
Urease production
Urease production was detected on Christensen’s urea agar
slopes after incubation for 24 h at 35C.
Detection of resistance genes by PCR
Preparation of whole-cell DNA for PCR, and amplification of
the aac6¢-aph2¢¢, ant4¢ and aph3¢ aminoglycoside resistance
genes was as described previously [25]. Amplification of the
macrolide resistance genes ermA, ermB and ermC was as
described previously [26], with primers for: ermA, 5¢-TAT-
CTTATCGTTGAGAAGGGATT-3¢ and 5¢-CTACACTTGGC-
TGATGAAA-3¢; ermB, 5¢-CTATCTGATTGTTGAAGAAGGA-
TT-3¢ and 5¢-GTTTACTCTTGGTTTAGGATGAAA-3¢; and
ermC, 5¢-AATCGTCAATTCCTGCATGT-3¢ and 5¢-TAATCG-
TGGAATACGGGTTTG-3¢. Strains WBG4483 (gentamicin-
resistant isolate carrying plasmid pWBG613, aac6¢-aph2¢¢) [27],
XU165 (kanamycin-resistant isolate carrying pUB110, ant4¢)
[27], WBG1022 (kanamycin-resistant isolate carrying pWBG626
(aph3¢) [28], WBG525 (ermA), WBG516 (carrying plasmid pI258,
ermB) [28] and WBG4882 (carrying PE194, ermC) [27] were
used as positive controls.
Detection of staphylococcal toxins
All isolates were screened for the production of staphylo-
coccal enterotoxins A, B, C and D (SEA, SEB, SEC and SED),
toxic shock syndrome toxin (TSST-1) and exfoliative toxins A
and B (ETA and ETB) with a reverse passive latex agglu-
tination kit (SET-RPLA; Oxoid), used according to the
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manufacturer’s instructions. The presence of the PVL genes,
lukS-lukF, was detected using the primers described previ-
ously [7]. A PVL-producing S. aureus strain, WBG10049 [22],
was used as a positive control.
SCCmec and ccr typing
The SCCmec type was revealed by PCR assays that determined
the mec complex [29] and the type of cassette chromosome
recombinase (ccr complex). Primers cB, cA1, cA2, cA3, C1 and
C2 were used as described previously [16]. The following
strains, kindly provided by W. B. Grubb (Curtin University,
Australia), were used as controls: COL (SCCmec type 1, ccr 2);
XU642 (EMRSA-16, SCCmec type II, ccr 2); WBG525 (EMRSA-1,
SCCmec type III) and WBG9465 (EMRSA-15, SCCmec type IV).
Pulsed-field gel electrophoresis (PFGE)
Counter-clamped homogenous electric field (CHEF) electro-
phoresis of SmaI-digested chromosomal DNA was performed
as described previously [30] in a CHEF-DRIII system (Bio-Rad,
Hercules, CA, USA) with a 5-s initial pulse and a 40-s final
pulse. SmaI-digested chromosomal DNA from S. aureus strain
NCTC 8325 was used as a molecular size marker. Following
electrophoresis, the gel was stained with ethidium bromide
0.5 mg ⁄L and photographed under ultraviolet illumination.
The chromosomal patterns were examined visually and
assigned to PFGE types.
RESULTS
Isolates and antibiotic susceptibilities
In total, 1457 MRSA were submitted for typing
between July 2001 and October 2003. Seventy-six
(5.2%) of these isolates were nmMRSA, or were
susceptible to most of the non-b-lactam antibiotics
tested. Forty-two of the 76 nmMRSA isolates,
consisting of single isolates from 40 patients and
two isolates (from blood and urine) from one
patient, were selected for further study. These
isolates were from various clinical samples, inclu-
ding wound swabs (n = 20), nasal swabs (n = 6),
skin swabs (n = 5), groin swabs (n = 3), urine
(n = 2) and blood (n = 2) samples, and one sam-
ple each from an ear, an eye, a tracheal aspirate
and an unspecified abscess, and were obtained
from AMH (n = 12), MAK (n = 10), ADH (n = 6),
ASH (n = 5), ARH (n = 4), JH (n = 3) and ISH
(n = 2). The 42 nmMRSA were characterised
further to determine their resistance patterns,
bacteriophage susceptibilities and urease produc-
tion, and by PFGE and SCCmec typing.
All 42 isolates were PBP2a-positive and were
resistant to methicillin (MIC range, 8–256 mg ⁄L),
penicillin G and cefoxitin. Except for seven isolates
that expressed high-level methicillin resistance
(MIC > 256 mg ⁄L), the isolates expressed low-
level methicillin resistance (MIC 8–32 mg ⁄L). All
isolateswere susceptible to vancomycin (MIC0.75–
3 mg ⁄L), teicoplanin (MIC 0.5–2 mg ⁄L), mupiro-
cin, rifampicin, fosfomycin, gentamicin, linezolid
and mercuric chloride. The resistance patterns are
summarised in Table 1. Thirteen (31%) isolates
were resistant to tetracycline, 13 (31%) to fusidic
acid, 11 (26%) to kanamycin, 11 (26%) to erythro-
mycin and clindamycin, nine (21.2%) to ciprofl-
oxacin, five (11.9%) to trimethoprim, and one
(2.4%) to chloramphenicol. Thirty-eight (91%)
isolates were resistant to cadmium acetate, and
seven (17%) were resistant to propamidine iseth-
ionate. Twelve (28.6%) isolates were resistant to
cadmium acetate, but were susceptible to all
non-b-lactam antibiotics tested.
All of the 11 kanamycin-resistant isolates
carried the aph(3¢) gene, but none contained
the ant(4¢) and aac(6¢)-aph (2¢) genes. Ten of the
11 erythromycin- and clindamycin-resistant iso-
lates contained the ermC gene. No amplification
product was obtained with any of the primers
for the three erm genes that were tested with the
eleventh isolate.
Table 1. Phenotypic and genotypic characteristics of non-
multiresistant methicillin-resistant Staphylococcus aureus
isolates
Antibiogram n SCCmec type ccr type PFGE type Urease
Kan, Fus, Tc, Cd 6 IV 2 A +
Kan, Fus, Cd 3 IV 2 A +
Kan, Fus, Cd 1 IV 2 A1 –
Kan, Cd 1 IV ND E +
Em, Cip, Cd, Pi 2 IV 2 D –
Em, Cip, Cd 1 IV 2 D1 –
Em, Cip, Cd 3 IV 2 D2 –
Em, Cip, Pi 1 IV 2 D –
Em, Tc, Cd 1 III ND C –
Em,Tc,Tp, Cd 1 IV 2 C1 +
Em,Tp, Cm 1 IV 2 D2 –
Em, Cd 1 IV 2 F +
Tc, Tp, Cd 2 IV 2 D1 –
Tc, Fus, Cd 1 IV 2 A +
Tc, Fus, Cd 1 IV 2 A2 +
Tc, Fus, Cd 1 IV 2 A3 +
Cip, Cd 1 IV 2 D2 –
Cip 1 IV 2 D –
Tp, Cd 1 IV 2 D1 –
Cd 8 IV 2 B +
Cd 1 IV 2 F +
Cd 1 IV 2 C +
Cd 1 IV 2 B –
Cd 1 IV 2 C2 +
Kan, kanamycin; Tc, tetracycline; Fus, fusidic acid; Ery, erythromycin; Cip,
ciprofloxacin; Tp, trimethoprim; Cd, cadmium acetate; Pi, propamidine isethionate;
SCCmec, staphylococcal cassette chromosome mec; ccr, cassette chromosome
recombinase gene; PFGE, pulsed-field gel electrophoresis; ND, not amplified with
any of the primers used.
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Bacteriophage typing
The bacteriophage patterns for individual urease-
positive and -negative isolates are shown in
Tables 2 and 3. Sixteen (38.0%) isolates were
untypeable with the international set of phages.
Twelve (24.0%) isolates had a weak reaction with
phage 75. The remaining isolates were lysed by
phages belonging to group I (five isolates), group
III (six isolates), or combinations of groups I, II
and III (three isolates).
Production of staphylococcal toxins
None of the isolates produced SEA, SEB, SED,
ETA or ETB. However, ten (23.8%) isolates
produced SEC and five isolates produced TSST-
1. The lukS-lukF genes were amplified from ten
(23.8%) of the 42 isolates (Tables 2 and 3).
SCCmec and ccr gene typing
Forty-one isolates were positive for type-IV
SCCmec, and one isolate (2856) was positive for
type-III SCCmec. Forty isolates had the type-2 ccr
gene complex. Two isolates, 2656 and 2856, did
not yield amplification products with any of the
primer pairs used, suggesting the existence of a
new ccr gene complex. All control strains gave the
expected results for SCCmec and ccr typing.
PFGE patterns of MRSA isolates
Six different PFGE patterns, designated types
A–F, were observed among the 42 isolates (Fig. 1).
The distribution of PFGE types in the different
hospitals is summarised in Tables 1, 2 and 3.
PFGE type A and its subtypes (13 isolates) was
shared by isolates from six hospitals. PFGE types
B and D were shared by isolates from four
hospitals. The other PFGE patterns were less
common and were restricted to isolates from one
or two hospitals. A comparison of PFGE types
with resistance patterns (Table 1) revealed that
nine of the 11 kanamycin-resistant isolates shared
a single PFGE pattern (type A), while one
belonged to PFGE type A1 and one belonged to
the unrelated PFGE type E. Eight of the 12
cadmium acetate-resistant isolates shared the
same PFGE pattern (type B). The erythromycin-
resistant isolates had three different PFGE
patterns.
Urease production
Most (n = 26; 61.9%) isolates produced urease.
The characteristics of the urease-producing and
non-producing isolates are presented in Tables 2
and 3, respectively. All of the urease-positive
isolates expressed low-level methicillin-resistance
(MIC 8–48 mg ⁄L). Nine were lukS-lukF-positive,
Table 2. Characteristics of urease-
positive methicillin-resistant Staphy-
lococcus aureus isolates
Strains Hospital Source Phage types MICa PVL SEC ⁄TSST PFGE type Resistant to
1839 JH Wound NT 16 + – ⁄ – F Ery, Cd
2086 JH Wound 71 24 + – ⁄ – A Kan, Fus, Cd
2116 MAK Wound 29 ⁄ 52 ⁄ 79 ⁄ 42E ⁄ 77 32 + – ⁄ – B Cd
2141 MAK Wound 52 ⁄ 52 A ⁄ 80 32 + – ⁄ – B Cd
2917 ARH Wound NT 32 + – ⁄ – A Kan, Tc, Fus, Cd
2827 ASH Wound 6 ⁄ 42E ⁄ 47 ⁄ 53 ⁄ 54 8 + – ⁄ – A Tc, Fus, Cd
2442 AMH Wound 42E ⁄ 77 ⁄ 81 16 + – ⁄ – B Cd
2402 AMH Wound N T 8 + – ⁄ – A3 Tc, Fus, Cd
2408 ADH Wound NT 8 + – ⁄+ B Cd
1814 ADH Groin 6 ⁄ 53 ⁄ 77 8 – – ⁄ – A Kan, Tc, Fus, Cd
1847 AMH Abscess NT 32 – – ⁄ – B Cd
1938 AMH Wound 29 ⁄ 52 ⁄ 52 A ⁄ 80 48 – – ⁄+ B Cd
1943 AMH Wound NT 16 – – ⁄ – A Kan, Tc, Fus, Cd
2005 MAK Groin 29 ⁄ 52 ⁄ 52 A ⁄ 79 ⁄ 80 32 – – ⁄ – B Cd
2076 ASH Wound 71 ⁄ 42E ⁄ 47 32 – – ⁄ – C2 Cd
2129 ASH Skin 47 8 – – ⁄+ A2 Tc, Fus, Cd
2220 AMH Wound 3C ⁄ 47 ⁄ 54 ⁄ 84 ⁄ 85 32 – – ⁄ – B Cd
2499 ADH Skin NT 16 – – ⁄ – A Kan, Tc, Fus, Cd
2565 AMH Wound NT 24 – – ⁄ – A Kan, Tc, Fus, Cd
2600 ASH Nose 54 48 – – ⁄ – C Cd
2656 ARH Wound 3C ⁄ 6 ⁄ 42E ⁄ 47 ⁄ 54 24 – – ⁄ – E Kan, Cd
2700 ADH Eye NT 8 – – ⁄ – A1 Kan, Fus, Cd
2945 MAK Groin NT 16 – – ⁄ – A Kan, Fus, Cd
2979 ISH Nose 53 ⁄ 54 ⁄ 81 16 – – ⁄ – F Cd
3290 ADH Skin NT 24 – – ⁄ – A Kan, Tc, Fus, Cd
3471 ADH Skin NT 16 – – ⁄ – C1 Ery,Tc,Tp,Cd
aMethicillin MIC (mg ⁄L).
ADH, Adan hospital; ASH, Al-Sabah hospital; AMH, Amiri hospital; ARH, Al-Razi hospital; JH, Jahra hospital;
MAK, Mubarak hospital; SEC, staphylococcal enterotoxin C; TSST, toxic shock syndrome toxin. Other abbreviations
as in Table 1.
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but none produced any of the staphylococcal
enterotoxins tested. However, three produced
TSST-1. Most of the urease-positive isolates were
from wound or skin samples, which are sources
usually associated with CA-MRSA [8,12,20], and
had a more varied bacteriophage pattern than
those of the urease-negative isolates. PFGE results
showed that they belonged to five PFGE types,
indicating that they were from heterogeneous
genetic backgrounds.
Twelve of the 16 urease-negative isolates
showed weak lysis with phage 75 of the interna-
tional typing set, with five isolates also showing
lysis with phage 42E. Ten produced SEC and two
produced TSST-1. Only one isolate, 2519, was
lukS-lukF-positive. The urease-negative isolates
were from more varied clinical sources than the
urease-positive isolates, and were more resistant
to erythromycin and ciprofloxacin. Nine of the 11
erythromycin-resistant isolates, and all nine
ciprofloxacin-resistant isolates, did not produce
urease. PFGE showed that these isolates belonged
to three PFGE types. Thirteen of the 16 isolates
belonged to PFGE type D (six isolates), or its
subtypes D1 (three isolates) and D2 (four isolates),
and were isolated in four hospitals. Their PFGE
pattern was related to EMRSA-15 (WBG9465)
(Fig. 1).
DISCUSSION
This study investigated 42 nmMRSA isolates
obtained between July 2001 and October 2003
from seven hospitals in Kuwait to determine
whether they were CA-MRSA. All of the isolates
studied were resistant to few non-b-lactam anti-
biotics and expressed low-level methicillin resist-
ance (MICs 6–32 mg ⁄L), similar to CA-MRSA
reported elsewhere [21], except for seven isolates
that expressed high-level methicillin resistance
(MIC > 256 mg ⁄L). In addition to antibiotic resist-
ance, 38 isolates, including 12 that were suscept-
ible to all the non-b-lactam agents tested, were
cadmium-resistant. Although it is not clear why
S. aureus carry determinants for cadmium resist-
Table 3. Characteristics of urease-negative methicillin-resistant Staphylococcus aureus isolates
Strains Hospital Source Phage types MICa SEC ⁄TSST PFGE type Resistant to
1888 ARH Nose 75w > 256 + ⁄ – D Ery, Cip, Pi
2058 AMH Urine 75w ⁄ 42E > 256 + ⁄ – D Ery, Cip, Cd, Pi
2059 AMH Nose 75w ⁄ 42E > 256 + ⁄ – D Ery, Cip, Cd, Pi
2100 MAK Urine NT 12 + ⁄ – D1 Tc, Tp, Cd
2204 AMH Nose 75w ⁄ 42E > 256 – ⁄+ D Cip
2260 AMH T ⁄ aspirate 75w ⁄ 42E > 256 + ⁄ – D Ery, Cip, Cd
2270 AMH Wound 75w > 256 + ⁄ – D2 Cip, Cd
2472 JH Wound 52 ⁄ 52 A ⁄ 80 32 – ⁄+ B Cd
2519b ASH Wound 75w 32 + ⁄ – A Kan, Fus, Cd
2538 MAK Blood 75w 32 + ⁄ – D2 Ery, Cip, Cd
2591 MAK Ear 75w 12 + ⁄ – D1 Tc, Tp, Cd
2621 ARH Wound 75w 48 – ⁄ – D Ery, Cip, Cd
2856 MAK Blood 75w 8 – ⁄ – C Ery, Tc, Cd
2967 MAK Wound 75w ⁄ 42E 8 – ⁄ – D2 Ery, Tp, Cm
2968 ISH Nose NT 24 – ⁄ – D1 Tp, Cd
3481 MAK Skin 52 ⁄ 52 A ⁄ 79 > 256 + ⁄ – D2 Ery, Cip, Cd
aMethicillin MIC (mg ⁄L).
bcarries lukS-lukf genes
Abbreviations as in Tables 1 and 2.
A    B   C    D   E    F   G   H     I    J    K    L   M   N   O
48.5
97.0
145.5
194.0
291.0
388.0
Fig. 1. PFGE patterns of representative non-multiresistant
methicillin-resistant Staphylococcus aureus isolates. Lanes:
A, PFGE type A; B, type A2; C, type A3; D, type B; E, type
B1; F, type C; G, type C1; H, type C2; I, type D; J, type D1;
K, type D2; L, type E; M, type F; N, EMRSA-15 (strain
WBG9465); O, Lambda DNA size marker (sizes are in kb).
Note the similarity between the type D isolates in lanes I, J,
K and EMRSA-15 in lane N.
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ance, CA-MRSA isolated from Australia have
been shown previously to carry plasmid-
mediated cadmium resistance [3,22], and cad-
mium resistance has been found on plasmids that
do not carry antibiotic resistance determinants
[3,28].
SCCmec and ccr gene complex analysis revealed
that 41 of the 42 isolates had a type-IV SCCmec,
and 40 harboured the type-2 ccr gene complex,
both of which are characteristics of CA-MRSA
[16,21,22]. However, tests for urease production
and phage-typing divided the isolates clearly into
two types. All isolates that produced urease
expressed low-level methicillin resistance (MIC
8–32 mg ⁄L) and had phage patterns that were
different from those of the urease-negative isolates.
These isolates belonged to different PFGE types
(Fig. 1) and were isolated mostly from wound
or skin specimens (Table 2). Nine carried the
lukS-lukF genes that encode PVL production.
CA-MRSA have been associated largely with
skin and soft-tissue infections and PVL produc-
tion [1,2,12]. These characteristics, together with
their susceptibility to most non-b-lactam antibiot-
ics and carriage of type-IV SCCmec and ccr
gene types, classified the urease-positive isolates
as CA-MRSA.
The CA-MRSA in this study belonged to differ-
ent genetic backgrounds, as demonstrated by
PFGE. Similarly, CA-MRSA from Australia
[21,22], the USA [2] and Europe [9,31] belonged
to diverse genetic backgrounds. Nevertheless, in
the present study, isolates belonging to two PFGE
types were present in at least four hospitals.
CA-MRSA have been associated with outbreaks
in Australia [10], France [11] and the USA [13],
suggesting that some CA-MRSA clones are evol-
ving with a greater capacity to spread. It is
interesting that the isolates in the present study
started to appear in 2001. Twelve of these
CA-MRSA isolates were fusidic acid-resistant,
and four of the fusidic acid-resistant isolates
contained genes for PVL (Table 2). Similarly,
fusidic acid-resistant, PVL-producing CA-MRSA
started to appear in Germany in 2002 [9]. The
CA-MRSA isolates from Germany were cipro-
floxacin-resistant, whereas the fusidic acid-
resistant CA-MRSA in the present study were
susceptible to ciprofloxacin.
Multilocus sequence typing (MLST) has
evolved in recent years to become the reference
method for comparing S. aureus isolates from
different geographical backgrounds [21,22,32,33].
The fusidic acid-resistant, PVL-producing MRSA
isolates from Germany belonged to sequence type
(ST) 80 [9]. Although the fusidic acid-resistant and
PVL-producing CA-MRSA in the present study
appear to be related to the ST80 strains from
Germany on the basis of their fusidic acid resist-
ance and PVL profiles, the MLST types of the
isolates from Kuwait have not yet been deter-
mined.
Currently, aminoglycoside resistance is rare
among CA-MRSA isolates [21]. Although the 42
isolates in this study were susceptible to gen-
tamicin, ten (38.5%) of the 26 CA-MRSA were
resistant to kanamycin because of inactivation by
the APH(3¢) enzyme. A recent comparison of the
susceptibility patterns of CA-MRSA from Eur-
ope, the USA, Australia and Oceania found
European isolates to be more resistant to kana-
mycin, tetracycline and fusidic acid than isolates
from the USA and Oceania [7]. These results,
together with the presence of kanamycin resist-
ance in 38.5% of the CA-MRSA in the present
study, may indicate that some CA-MRSA are
expanding their resistance pool to include amino-
glycoside resistance.
The urease-negative isolates had characteris-
tics consistent with those of the EMRSA-15
isolates found in the UK [34]. EMRSA-15 isolates
are characterised by weak lysis with phage 75,
production of enterotoxin C (SEC), non-produc-
tion of urease, and resistance to erythromyin
and ⁄ or ciprofloxacin [34–36]. Twelve of the 16
urease-negative isolates in the present study
showed weak lysis with phage 75, ten produced
SEC, nine were erythromycin-resistant, and
nine were ciprofloxacin-resistant. Two of
these isolates were untypeable with the interna-
tional typing set of phages, and two others were
susceptible to phages 52 ⁄ 52A ⁄ 79 and 52 ⁄ 52A ⁄ 80.
Although EMRSA-15 was identified initially by
weak lysis with phage 75, production of entero-
toxin C (SEC) and a negative urease test [34],
variants with broader phage patterns or loss of
phage reactivity have emerged in recent years
[36,37]. Similarly, EMRSA-15 variants that have
lost SEC production have also been reported
[35]. It has been suggested that the genes for SEC
production reside in a c. 15-kb mobile genetic
element. The loss of this mobile genetic element
results in the loss of SEC production in
SEC-negative EMRSA-15 variants [35]. Therefore,
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the EMRSA-15 isolates reported in the present
study included both classical and variant forms
of EMRSA-15 [34,36].
Although the urease-negative isolates be-
longed to three PFGE patterns, most (13 of 16
isolates) were homogeneous and belonged to
type D or its subtypes. They were also related to
a known EMRSA-15 strain (Fig. 1, lane N),
further supporting their identification as
EMRSA-15. One of the EMRSA-15 isolates was
positive for genes encoding PVL production,
which has been associated mostly with
CA-MRSA causing skin and soft-tissue infections
[8,12,20] and necrotising pneumonia [8,18]. How-
ever, PVL genes have also been detected in
EMRSA-15 (ST22) isolated in The Netherlands
[38], and in methicillin-susceptible S. aureus iso-
lates that are closely related to EMRSA-15 in the
UK [39]. These reports suggest that the PVL
genes are also beginning to appear in HA-MRSA
isolates. This is not surprising since the genes
for PVL production are encoded by a bacterio-
phage that can be transferred among strains
[40,41]. Nevertheless, it is a worrying develop-
ment, as the presence of PVL genes may
increase the virulence and severity of HA-MRSA
infections.
EMRSA-15 is one of the two most important
MRSA strains in the UK, constituting 60% and
70% of MRSA isolated in England and Scotland,
respectively [42], and has also been isolated in
The Netherlands [38], the Czech Republic [43],
Australia and New Zealand [43,44]. Its detection
in Kuwait hospitals suggests that it may also be
present in other Gulf countries, which is further
testimony to the epidemic nature of this MRSA
strain.
In conclusion, this study identified two types
of nmMRSA among the MRSA isolated in
Kuwait hospitals since 2001. The first type
produced urease and had characteristics of
CA-MRSA reported from other countries
[16,21,22]. The second type did not produce
urease and had the characteristics of the
EMRSA-15 strain, first described in the UK
[34] and also reported in other countries in
Europe [38,40–43], Australia and New Zealand
[44,45]. The isolation of EMRSA-15 in Kuwait
emphasises the epidemic nature of this strain.
The study demonstrated the ability of CA-
MRSA and EMRSA-15 to coexist and circulate
within the hospital environment.
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